BSLN — Basilea Pharmaceutica AG, Allschwil Share News
0.000.00%
Last trade - 00:00- CH₣888.06m
- CH₣785.65m
- CH₣232.38m
Brief: Basilea's Partner Asahi Kasei Files For Isavuconazole Authorization In Japan
Swiss stocks - Factors to watch on July 26
Brief: Basilea Announces Distribution Agreement With JSC Lancet For Antibiotic Zevtera® (Ceftobiprole)
Brief: Basilea Reports New Prevalence Data For EB1 In Glioblastoma And Other Tumor Types
Brief: Basilea Announces Positive Data On Derazantinib As Monotherapy In iCCA
Brief: Basilea Gets Carb-X Grant Of Up To USD 2.7 Mln To Develop Novel-Class Antibiotic
Swiss stocks - Factors to watch on April 22
Brief: Basilea Shareholders Approve All Proposals Of Board Of Directors At Annual General Meeting
Swiss stocks - Factors to watch on March 24
Brief: Basilea Reports Positive Interim Results From Phase 2 Study Fides-01 For Derazantinib In FGFR2 Gene Mutation
Brief: Basilea Raised Gross Proceeds Of CHF 45.75 Million
Swiss stocks - Factors to watch on February 24
Brief: Basilea Pharmaceutica Primary ABB Price Guidance CHF 45.75 - Bookrunner
Brief: Basilea Pharmaceutica Primary ABB Books Are Oversubscribed - Bookrunner
Brief: Basilea Pharmaceutica Launches Private Placement Of New Shares
Brief: Basilea Pharmaceutica FY Operating Loss Down 52% To CHF 8.2 Million
Brief: Basilea Pharmaceutica Announces Divestment Of Its Chinese Research And Development
Brief: Basilea To Start Clinical Studies On Kinase Inhibitor
Brief: Basilea Pharmaceutica Sales Trigger Milestone From Pfizer To Basilea Of USD 10 Million